507 related articles for article (PubMed ID: 24938562)
1. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
Carvajal RD; Sosman JA; Quevedo JF; Milhem MM; Joshua AM; Kudchadkar RR; Linette GP; Gajewski TF; Lutzky J; Lawson DH; Lao CD; Flynn PJ; Albertini MR; Sato T; Lewis K; Doyle A; Ancell K; Panageas KS; Bluth M; Hedvat C; Erinjeri J; Ambrosini G; Marr B; Abramson DH; Dickson MA; Wolchok JD; Chapman PB; Schwartz GK
JAMA; 2014 Jun; 311(23):2397-405. PubMed ID: 24938562
[TBL] [Abstract][Full Text] [Related]
2. Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).
Carvajal RD; Schwartz GK; Mann H; Smith I; Nathan PD
BMC Cancer; 2015 Jun; 15():467. PubMed ID: 26059332
[TBL] [Abstract][Full Text] [Related]
3. Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).
Carvajal RD; Piperno-Neumann S; Kapiteijn E; Chapman PB; Frank S; Joshua AM; Piulats JM; Wolter P; Cocquyt V; Chmielowski B; Evans TRJ; Gastaud L; Linette G; Berking C; Schachter J; Rodrigues MJ; Shoushtari AN; Clemett D; Ghiorghiu D; Mariani G; Spratt S; Lovick S; Barker P; Kilgour E; Lai Z; Schwartz GK; Nathan P
J Clin Oncol; 2018 Apr; 36(12):1232-1239. PubMed ID: 29528792
[TBL] [Abstract][Full Text] [Related]
4. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
Kirkwood JM; Bastholt L; Robert C; Sosman J; Larkin J; Hersey P; Middleton M; Cantarini M; Zazulina V; Kemsley K; Dummer R
Clin Cancer Res; 2012 Jan; 18(2):555-67. PubMed ID: 22048237
[TBL] [Abstract][Full Text] [Related]
5. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
6. Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.
Jänne PA; van den Heuvel MM; Barlesi F; Cobo M; Mazieres J; Crinò L; Orlov S; Blackhall F; Wolf J; Garrido P; Poltoratskiy A; Mariani G; Ghiorghiu D; Kilgour E; Smith P; Kohlmann A; Carlile DJ; Lawrence D; Bowen K; Vansteenkiste J
JAMA; 2017 May; 317(18):1844-1853. PubMed ID: 28492898
[TBL] [Abstract][Full Text] [Related]
7. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.
Ascierto PA; Long GV; Robert C; Brady B; Dutriaux C; Di Giacomo AM; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Savage KJ; Hernberg MM; Lebbé C; Charles J; Mihalcioiu C; Chiarion-Sileni V; Mauch C; Cognetti F; Ny L; Arance A; Svane IM; Schadendorf D; Gogas H; Saci A; Jiang J; Rizzo J; Atkinson V
JAMA Oncol; 2019 Feb; 5(2):187-194. PubMed ID: 30422243
[TBL] [Abstract][Full Text] [Related]
8. Uveal melanoma therapy on the horizon?
Cancer Discov; 2014 Sep; 4(9):OF6. PubMed ID: 25185205
[TBL] [Abstract][Full Text] [Related]
9. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Stupp R; Taillibert S; Kanner A; Read W; Steinberg D; Lhermitte B; Toms S; Idbaih A; Ahluwalia MS; Fink K; Di Meco F; Lieberman F; Zhu JJ; Stragliotto G; Tran D; Brem S; Hottinger A; Kirson ED; Lavy-Shahaf G; Weinberg U; Kim CY; Paek SH; Nicholas G; Bruna J; Hirte H; Weller M; Palti Y; Hegi ME; Ram Z
JAMA; 2017 Dec; 318(23):2306-2316. PubMed ID: 29260225
[TBL] [Abstract][Full Text] [Related]
10. Selumetinib shows promise in metastatic uveal melanoma.
Cancer Discov; 2013 Jul; 3(7):OF8. PubMed ID: 23847383
[TBL] [Abstract][Full Text] [Related]
11. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Stupp R; Taillibert S; Kanner AA; Kesari S; Steinberg DM; Toms SA; Taylor LP; Lieberman F; Silvani A; Fink KL; Barnett GH; Zhu JJ; Henson JW; Engelhard HH; Chen TC; Tran DD; Sroubek J; Tran ND; Hottinger AF; Landolfi J; Desai R; Caroli M; Kew Y; Honnorat J; Idbaih A; Kirson ED; Weinberg U; Palti Y; Hegi ME; Ram Z
JAMA; 2015 Dec; 314(23):2535-43. PubMed ID: 26670971
[TBL] [Abstract][Full Text] [Related]
12. Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma.
Atkinson TM; Hay JL; Shoushtari A; Li Y; Paucar DJ; Smith SC; Kudchadkar RR; Doyle A; Sosman JA; Quevedo JF; Milhem MM; Joshua AM; Linette GP; Gajewski TF; Lutzky J; Lawson DH; Lao CD; Flynn PJ; Albertini MR; Sato T; Lewis K; Marr B; Abramson DH; Dickson MA; Schwartz GK; Carvajal RD
J Cancer Res Clin Oncol; 2017 Mar; 143(3):439-445. PubMed ID: 27921276
[TBL] [Abstract][Full Text] [Related]
13. Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial.
Chung V; McDonough S; Philip PA; Cardin D; Wang-Gillam A; Hui L; Tejani MA; Seery TE; Dy IA; Al Baghdadi T; Hendifar AE; Doyle LA; Lowy AM; Guthrie KA; Blanke CD; Hochster HS
JAMA Oncol; 2017 Apr; 3(4):516-522. PubMed ID: 27978579
[TBL] [Abstract][Full Text] [Related]
14. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
[TBL] [Abstract][Full Text] [Related]
15. DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.
Gupta A; Love S; Schuh A; Shanyinde M; Larkin JM; Plummer R; Nathan PD; Danson S; Ottensmeier CH; Lorigan P; Collins L; Wise A; Asher R; Lisle R; Middleton MR
Ann Oncol; 2014 May; 25(5):968-74. PubMed ID: 24567366
[TBL] [Abstract][Full Text] [Related]
16. Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201).
Luke JJ; Olson DJ; Allred JB; Strand CA; Bao R; Zha Y; Carll T; Labadie BW; Bastos BR; Butler MO; Hogg D; Munster PN; Schwartz GK
Clin Cancer Res; 2020 Feb; 26(4):804-811. PubMed ID: 31558480
[TBL] [Abstract][Full Text] [Related]
17. Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives.
Komatsubara KM; Manson DK; Carvajal RD
Future Oncol; 2016 Jun; 12(11):1331-44. PubMed ID: 27044592
[TBL] [Abstract][Full Text] [Related]
18. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
Hauschild A; Grob JJ; Demidov LV; Jouary T; Gutzmer R; Millward M; Rutkowski P; Blank CU; Miller WH; Kaempgen E; Martín-Algarra S; Karaszewska B; Mauch C; Chiarion-Sileni V; Martin AM; Swann S; Haney P; Mirakhur B; Guckert ME; Goodman V; Chapman PB
Lancet; 2012 Jul; 380(9839):358-65. PubMed ID: 22735384
[TBL] [Abstract][Full Text] [Related]
19. A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.
LoRusso PM; Infante JR; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; Cohen RB
BMC Cancer; 2017 Mar; 17(1):173. PubMed ID: 28264648
[TBL] [Abstract][Full Text] [Related]
20. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
Xia C; Leon-Ferre R; Laux D; Deutsch J; Smith BJ; Frees M; Milhem M
Cancer Chemother Pharmacol; 2014 Oct; 74(4):691-7. PubMed ID: 25062770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
